VOR - Vor Biopharma Inc.

14.56
-0.490   -3.365%

Share volume: 464,331
Last Updated: 03-05-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$15.05
-0.49
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 35%
Dept financing 43%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-8.43%
1 Month
10.64%
3 Months
74.16%
6 Months
635.35%
1 Year
1,378.17%
2 Year
1,093.44%
Key data
Stock price
$14.56
P/E Ratio 
0.00
DAY RANGE
$14.04 - $15.15
EPS 
-$122.33
52 WEEK RANGE
$0.13 - $49.95
52 WEEK CHANGE
$1,356.00
MARKET CAP 
308.600 M
YIELD 
N/A
SHARES OUTSTANDING 
10.411 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$678,409
AVERAGE 30 VOLUME 
$706,737
Company detail
CEO: Bob Ang
Region: US
Website: vorbio.com
Employees: 140
IPO year: 2021
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Recent news